Deals: Page 3
-
Mario Tama via Getty Images
J&J to buy Proteologix and its dual-targeting antibody drugs for $850M
The deal is part of a plan by J&J to build a portfolio of “differentiated” bispecific antibodies, an increasingly popular area of drug development.
By Kristin Jensen • May 16, 2024 -
selvanegra via Getty Images
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
The deal — worth $100 million up front and potentially billions more later on — gives Takeda an exclusive option to license an Alzheimer’s vaccine and other “active immunotherapies.”
By Jacob Bell • May 13, 2024 -
Courtesy of Sanofi
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
The deal gives the pharma partial rights to a medicine GSK once developed for heart disease but could soon become the first therapy for facioscapulohumeral muscular dystrophy.
By Jonathan Gardner • May 13, 2024 -
Permission granted by Maze Therapeutics
Maze lands new partner for Pompe drug, after Sanofi pact came apart
An alliance with Shionogi involves similar terms as a deal Sanofi canceled in response to an unusual challenge from the Federal Trade Commission.
By Ben Fidler • May 10, 2024 -
Courtesy of Sanofi
Royalty Pharma pays startup $525M for stake in Sanofi MS drug
The deal gives the company milestone payments and royalties to a medicine, frexalimab, that Sanofi licensed from biotech ImmuNext and expects to be a future blockbuster.
By Kristin Jensen • May 9, 2024 -
Courtesy of Novo Nordisk
Novo taps another Flagship startup in search for next obesity drugs
The deal with Metaphore Biotechnologies is the third from a Flagship alliance meant to boost the Danish drugmaker’s pipeline of weight loss medicines.
By Gwendolyn Wu • May 9, 2024 -
Mohammed Haneefa Nizamudeen via Getty Images
Gossamer sells rights to drug it hopes can rival a new Merck therapy
One analyst thinks the collaboration “bodes well” for Gossamer, which has had trouble convincing investors its drug seralutinib can compete on the market.
By Jacob Bell • May 6, 2024 -
Novartis
Why selling to Novartis made sense for Mariana
Conversations at this year's J.P. Morgan Healthcare Conference led to a $1 billion buyout that Mariana's CEO described as a "perfect marriage."
By Ned Pagliarulo • May 3, 2024 -
Novartis
Novartis to buy Mariana Oncology in radiopharmaceutical expansion
The $1 billion dollar acquisition will add to Novartis’ pipeline of the targeted radiation drugs, giving it a potential lung cancer treatment.
By Delilah Alvarado • May 2, 2024 -
Elizabeth Regan / Industry Dive
Deciphera to sell for $2.4B, adding to upswing in biopharma M&A
For Japan-based Ono Pharmaceutical, buying Deciphera offers a way to build out in cancer research as well as get a stronger foothold in the U.S. and European markets.
By Jacob Bell • April 29, 2024 -
Permission granted by Biogen
Biogen: Don’t expect any big acquisitions this year
While the company is eager to diversify, CEO Chris Viehbacher said any near-term dealmaking would likely focus on collaborations and early-stage assets.
By Jacob Bell • April 24, 2024 -
Courtesy of Ipsen
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA.
By Delilah Alvarado • April 22, 2024 -
selvanegra via Getty Images
Eisai hunts for next Alzheimer’s drug with new research pact
A collaboration with BioArctic will focus on a technology designed to more effectively deliver drugs in the brain, following similar efforts by Roche.
By Jonathan Gardner • April 22, 2024 -
Courtesy of Teva Pharmaceutical
Alvotech deal could heighten biosimilar pressure on Humira
The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.
By Jonathan Gardner • April 19, 2024 -
Nemes Laszlo via Getty Images
Roche, Adaptimmune part ways on cell therapy research
The two companies have ended a collaboration that was struck in 2021 and focused on “off-the-shelf” cell therapies for cancer.
By Jacob Bell • April 12, 2024 -
luismmolina via Getty Images
Century buys a startup, raises funding in cell therapy expansion
The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.
By Delilah Alvarado • April 11, 2024 -
Permission granted by Vertex Pharmaceuticals
Vertex to buy kidney disease drugmaker Alpine for $4.9B
A proposed $4.9 billion buyout of Alpine Immune Sciences would be the largest ever acquisition for Vertex and align with its "toolkit of technologies" approach to dealmaking.
By Gwendolyn Wu • Updated April 11, 2024 -
Mario Tama via Getty Images
J&J to acquire Shockwave Medical for $13.1B
The deal comes just over a week after The Wall Street Journal reported the companies were discussing a merger.
By Ricky Zipp • Updated April 5, 2024 -
Love Employee via Getty Images
Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry
The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.
By Kristin Jensen • April 3, 2024 -
Michael M. Santiago via Getty Images
Acorda files for bankruptcy, reveals asset sale plan
Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.
By Jacob Bell • April 2, 2024 -
Permission granted by Cardior
‘The heart is back,’ says Cardior CEO, as Novo’s $1B deal boosts field
Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior head Claudia Ulbrich.
By Michael Gibney • March 28, 2024 -
Courtesy of AbbVie
AbbVie to buy immune drug developer Landos
Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.
By Delilah Alvarado • March 25, 2024 -
hapabapa via Getty Images
Novo to acquire heart failure drug in $1B deal for Cardior
Cardior’s therapy is currently in mid-stage testing and, should the deal close, Novo plans to start another Phase 2 trial.
By Ned Pagliarulo • March 25, 2024 -
Courtesy of Thermo Fisher Scientific
Thermo Fisher, Bayer partner to develop companion diagnostics
The companies aim to identify potential patients for Bayer’s precision cancer therapies and increase access to the treatments.
By Nick Paul Taylor • March 21, 2024 -
Dr_Microbe via Getty Images
AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion
The deal hands AstraZeneca a prostate cancer drug that’s designed differently than Novartis’ fast-selling Pluvicto and currently in mid-stage testing.
By Ben Fidler • March 19, 2024
Previous
